Karl Naegler is a Principal in the life sciences sector, and joined Atlas Venture in 2002.
Previously, he worked as a Scientific Fellow at the Centre National de Recherche Scientifique, Centre for Neurochemistry, in Strasbourg, France.
Karl holds an MSc in Biology with distinction from the Free University of Berlin. During his studies he participated for one year in the honors program in biochemistry of Monash University in Melbourne, Australia. He obtained a PhD (summa cum laude) for his work in the area of molecular neurobiology at the Max-Delbrück-Center for Molecular Medicine (MDC) Berlin. Karl has also contributed to publications in highly respected scientific journals, including Science. This work has led to several patent applications.
Karl works closely with portfolio companies Egalet, F-Star, Nitec Pharma, Shogoo Pharmaceuticals, and U3 Pharma.
Investment Sector : Life Sciences
Portfolio Companies :
Egalet, f-star, Nitec Pharma, Shogoo Pharmaceuticals KK, U3 Pharma
In the News:
Danish Biotech Company Egalet Strengthens Management by Appointing Internationally Experienced CFO